Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate

Semin Oncol. 1994 Feb;21(1 Suppl 1):48-53.

Authors

R Rosell¹, J Gómez-Codina, A Anton, J J Sánchez, C Vadell

Affiliation

¹ Spanish Lung Cancer Group, Medical Oncology Unit, Germans Trias i Pujol University Hospital, Badalona, Spain.

PMID: 8153657

No abstract available

Publication types

Clinical Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Small Cell / drug therapy*
Cisplatin / administration & dosage*
Dose-Response Relationship, Drug
Epirubicin / administration & dosage*
Epirubicin / adverse effects
Female
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
Humans
Lung Neoplasms / drug therapy*
Male

Substances

Epirubicin
Granulocyte-Macrophage Colony-Stimulating Factor
Cisplatin